BioSpace News Archive

Brickell Biotech, Inc., a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced financial results for the second quarter ended June 30, 2021 and provided a corporate update.

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the second quarter ended June 30, 2021 and provided clinical development and operational highlights.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, reported recent business progress and second quarter financial results.

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced financial results for the second quarter and six months ended June 30, 2021 and provided an update on recent developments.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and men, today announced the appointment of Uneek Mehra as Chief Financial and Business Officer of Myovant Sciences, Inc.

Iridex Corporation reported financial results for the second quarter ended July 3, 2021.

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, reported results for the second quarter of 2021.

Relay Therapeutics, Inc., a clinical-stage precision medicine company transforming the drug discovery process by combining leading edge computational and experimental technologies, provided an update on its PI3Kα mutant selective program, reported second quarter 2021 financial results and announced a collaboration with EQRx.

Progenity, Inc., a biotechnology company innovating in the fields of gastrointestinal health and oral biotherapeutics, provided a corporate update and reported financial results for the second quarter ended June 30, 2021.

Tempest Therapeutics, Inc., a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, reported financial results and provided a corporate update for the second quarter ended June 30, 2021.